NCT07007273

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (estimated)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).

Conditions

• Cutaneous Sarcoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Outpatient infusion

Timeline

• Start date: 2025-06-20
• Primary completion: 2030-07-01
• Completion: 2030-07-01
• First posted: 2025-06-05
• Last updated: 2026-04-01

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study